BioLight Life Sciences Management
Management criteria checks 4/4
BioLight Life Sciences' CEO is Yaacov Michlin, appointed in May 2020, has a tenure of 4.67 years. total yearly compensation is ₪1.31M, comprised of 78.8% salary and 21.2% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth ₪296.10K. The average tenure of the management team and the board of directors is 5.1 years and 6.8 years respectively.
Key information
Yaacov Michlin
Chief executive officer
₪1.3m
Total compensation
| CEO salary percentage | 78.8% |
| CEO tenure | 4.7yrs |
| CEO ownership | 1.1% |
| Management average tenure | 5.1yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -₪6m |
| Mar 31 2024 | n/a | n/a | -₪24m |
| Dec 31 2023 | ₪1m | ₪1m | -₪26m |
| Sep 30 2023 | n/a | n/a | -₪28m |
| Jun 30 2023 | n/a | n/a | -₪29m |
| Mar 31 2023 | n/a | n/a | -₪10m |
| Dec 31 2022 | ₪2m | ₪1m | -₪8m |
| Sep 30 2022 | n/a | n/a | -₪7m |
| Jun 30 2022 | n/a | n/a | -₪5m |
| Mar 31 2022 | n/a | n/a | -₪3m |
| Dec 31 2021 | ₪1m | ₪969k | ₪382k |
Compensation vs Market: Yaacov's total compensation ($USD357.05K) is about average for companies of similar size in the IL market ($USD425.15K).
Compensation vs Earnings: Yaacov's compensation has been consistent with company performance over the past year.
CEO
Yaacov Michlin (55 yo)
4.7yrs
Tenure
₪1,305,000
Compensation
Mr. Yaacov Michlin serves as Director at AEYE Health Inc. He serves as Chairman at Peripherex. He was the Chief Executive Officer of Brainsway Ltd. from April 2017 until September 2019.Mr. Michlin was the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.7yrs | ₪1.31m | 1.07% ₪ 296.1k | |
| Chief Financial Officer | 9.7yrs | ₪744.00k | no data | |
| VP, Legal Advisor | no data | ₪659.00k | no data | |
| Chief Medical Officer & Member of Scientific Advisory Board | 5.1yrs | no data | no data |
5.1yrs
Average Tenure
54yo
Average Age
Experienced Management: BOLT's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Medical Officer & Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of the Board | 13.8yrs | ₪432.00k | 14.03% ₪ 3.9m | |
| Independent External Director | less than a year | no data | no data | |
| Independent External Director | 6.8yrs | no data | no data | |
| Vice Chairman of the Board | 4.5yrs | ₪225.00k | no data | |
| Independent External Director | 4.8yrs | no data | no data | |
| Independent Director | 9.5yrs | ₪149.00k | no data | |
| Independent Director | 7.7yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.8yrs
Average Tenure
61yo
Average Age
Experienced Board: BOLT's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 00:23 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioLight Life Sciences Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pooya Hemami | Edison Investment Research |
| Brian Murphy | Merriman Capital, Inc |
| Brian Marckx | Zacks Investment Research Inc. |